Cargando…
Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents (18)F-flutemetamol and (18)F-florbetaben
BACKGROUND: Although amyloid beta (Aβ) imaging is widely used for diagnosing and monitoring Alzheimer’s disease in clinical fields, paralleling comparison between (18)F-flutemetamol and (18)F-florbetaben was rarely attempted in AD mouse model. We performed a comparison of Aβ PET images between (18)F...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063010/ https://www.ncbi.nlm.nih.gov/pubmed/30053803 http://dx.doi.org/10.1186/s12868-018-0447-7 |
_version_ | 1783342481215062016 |
---|---|
author | Son, Hye Joo Jeong, Young Jin Yoon, Hyun Jin Lee, Sang Yoon Choi, Go-Eun Park, Ji-Ae Kim, Min Hwan Lee, Kyo Chul Lee, Yong Jin Kim, Mun Ki Cho, Kook Kang, Do-Young |
author_facet | Son, Hye Joo Jeong, Young Jin Yoon, Hyun Jin Lee, Sang Yoon Choi, Go-Eun Park, Ji-Ae Kim, Min Hwan Lee, Kyo Chul Lee, Yong Jin Kim, Mun Ki Cho, Kook Kang, Do-Young |
author_sort | Son, Hye Joo |
collection | PubMed |
description | BACKGROUND: Although amyloid beta (Aβ) imaging is widely used for diagnosing and monitoring Alzheimer’s disease in clinical fields, paralleling comparison between (18)F-flutemetamol and (18)F-florbetaben was rarely attempted in AD mouse model. We performed a comparison of Aβ PET images between (18)F-flutemetamol and (18)F-florbetaben in a recently developed APPswe mouse model, C57BL/6-Tg (NSE-hAPPsw) Korl. RESULTS: After an injection (0.23 mCi) of (18)F-flutemetamol and (18)F-florbetaben at a time interval of 2–3 days, we compared group difference of SUVR and kinetic parameters between the AD (n = 7) and control (n = 7) mice, as well as between (18)F-flutemetamol and (18)F-florbetaben image. In addition, bio-distribution and histopathology were conducted. With visual image and VOI-based SUVR analysis, the AD group presented more prominent uptake than did the control group in both the (18)F-florbetaben and (18)F-flutemetamol images. With kinetic analysis, the (18)F-florbetaben images showed differences in K1 and k4 between the AD and control groups, although (18)F-flutemetamol images did not show significant difference. (18)F-florbetaben images showed more prominent cortical uptake and matched well to the thioflavin S staining images than did the (18)F-flutemetamol image. In contrast, (18)F-flutemetamol images presented higher K1, k4, K1/k2 values than those of (18)F-florbetaben images. Also, (18)F-flutemetamol images presented prominent uptake in the bowel and bladder, consistent with higher bio-distribution in kidney, lung, blood and heart. CONCLUSIONS: Compared with (18)F-flutemetamol images, (18)F-florbetaben images showed prominent visual uptake intensity, SUVR, and higher correlations with the pathology. In contrast, (18)F-flutemetamol was more actively metabolized than was (18)F-florbetaben (Son et al. in J Nucl Med 58(Suppl 1):S278, 2017]. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12868-018-0447-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6063010 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60630102018-07-31 Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents (18)F-flutemetamol and (18)F-florbetaben Son, Hye Joo Jeong, Young Jin Yoon, Hyun Jin Lee, Sang Yoon Choi, Go-Eun Park, Ji-Ae Kim, Min Hwan Lee, Kyo Chul Lee, Yong Jin Kim, Mun Ki Cho, Kook Kang, Do-Young BMC Neurosci Research Article BACKGROUND: Although amyloid beta (Aβ) imaging is widely used for diagnosing and monitoring Alzheimer’s disease in clinical fields, paralleling comparison between (18)F-flutemetamol and (18)F-florbetaben was rarely attempted in AD mouse model. We performed a comparison of Aβ PET images between (18)F-flutemetamol and (18)F-florbetaben in a recently developed APPswe mouse model, C57BL/6-Tg (NSE-hAPPsw) Korl. RESULTS: After an injection (0.23 mCi) of (18)F-flutemetamol and (18)F-florbetaben at a time interval of 2–3 days, we compared group difference of SUVR and kinetic parameters between the AD (n = 7) and control (n = 7) mice, as well as between (18)F-flutemetamol and (18)F-florbetaben image. In addition, bio-distribution and histopathology were conducted. With visual image and VOI-based SUVR analysis, the AD group presented more prominent uptake than did the control group in both the (18)F-florbetaben and (18)F-flutemetamol images. With kinetic analysis, the (18)F-florbetaben images showed differences in K1 and k4 between the AD and control groups, although (18)F-flutemetamol images did not show significant difference. (18)F-florbetaben images showed more prominent cortical uptake and matched well to the thioflavin S staining images than did the (18)F-flutemetamol image. In contrast, (18)F-flutemetamol images presented higher K1, k4, K1/k2 values than those of (18)F-florbetaben images. Also, (18)F-flutemetamol images presented prominent uptake in the bowel and bladder, consistent with higher bio-distribution in kidney, lung, blood and heart. CONCLUSIONS: Compared with (18)F-flutemetamol images, (18)F-florbetaben images showed prominent visual uptake intensity, SUVR, and higher correlations with the pathology. In contrast, (18)F-flutemetamol was more actively metabolized than was (18)F-florbetaben (Son et al. in J Nucl Med 58(Suppl 1):S278, 2017]. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12868-018-0447-7) contains supplementary material, which is available to authorized users. BioMed Central 2018-07-27 /pmc/articles/PMC6063010/ /pubmed/30053803 http://dx.doi.org/10.1186/s12868-018-0447-7 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Son, Hye Joo Jeong, Young Jin Yoon, Hyun Jin Lee, Sang Yoon Choi, Go-Eun Park, Ji-Ae Kim, Min Hwan Lee, Kyo Chul Lee, Yong Jin Kim, Mun Ki Cho, Kook Kang, Do-Young Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents (18)F-flutemetamol and (18)F-florbetaben |
title | Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents (18)F-flutemetamol and (18)F-florbetaben |
title_full | Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents (18)F-flutemetamol and (18)F-florbetaben |
title_fullStr | Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents (18)F-flutemetamol and (18)F-florbetaben |
title_full_unstemmed | Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents (18)F-flutemetamol and (18)F-florbetaben |
title_short | Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents (18)F-flutemetamol and (18)F-florbetaben |
title_sort | assessment of brain beta-amyloid deposition in transgenic mouse models of alzheimer’s disease with pet imaging agents (18)f-flutemetamol and (18)f-florbetaben |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063010/ https://www.ncbi.nlm.nih.gov/pubmed/30053803 http://dx.doi.org/10.1186/s12868-018-0447-7 |
work_keys_str_mv | AT sonhyejoo assessmentofbrainbetaamyloiddepositionintransgenicmousemodelsofalzheimersdiseasewithpetimagingagents18fflutemetamoland18fflorbetaben AT jeongyoungjin assessmentofbrainbetaamyloiddepositionintransgenicmousemodelsofalzheimersdiseasewithpetimagingagents18fflutemetamoland18fflorbetaben AT yoonhyunjin assessmentofbrainbetaamyloiddepositionintransgenicmousemodelsofalzheimersdiseasewithpetimagingagents18fflutemetamoland18fflorbetaben AT leesangyoon assessmentofbrainbetaamyloiddepositionintransgenicmousemodelsofalzheimersdiseasewithpetimagingagents18fflutemetamoland18fflorbetaben AT choigoeun assessmentofbrainbetaamyloiddepositionintransgenicmousemodelsofalzheimersdiseasewithpetimagingagents18fflutemetamoland18fflorbetaben AT parkjiae assessmentofbrainbetaamyloiddepositionintransgenicmousemodelsofalzheimersdiseasewithpetimagingagents18fflutemetamoland18fflorbetaben AT kimminhwan assessmentofbrainbetaamyloiddepositionintransgenicmousemodelsofalzheimersdiseasewithpetimagingagents18fflutemetamoland18fflorbetaben AT leekyochul assessmentofbrainbetaamyloiddepositionintransgenicmousemodelsofalzheimersdiseasewithpetimagingagents18fflutemetamoland18fflorbetaben AT leeyongjin assessmentofbrainbetaamyloiddepositionintransgenicmousemodelsofalzheimersdiseasewithpetimagingagents18fflutemetamoland18fflorbetaben AT kimmunki assessmentofbrainbetaamyloiddepositionintransgenicmousemodelsofalzheimersdiseasewithpetimagingagents18fflutemetamoland18fflorbetaben AT chokook assessmentofbrainbetaamyloiddepositionintransgenicmousemodelsofalzheimersdiseasewithpetimagingagents18fflutemetamoland18fflorbetaben AT kangdoyoung assessmentofbrainbetaamyloiddepositionintransgenicmousemodelsofalzheimersdiseasewithpetimagingagents18fflutemetamoland18fflorbetaben |